Short hairpin RNA (shRNA) of type 2 interleukin-1 receptor (IL1R2) inhibits the proliferation of human osteosarcoma U-2 OS cells

Medical Oncology

Volumn 32, Issue 1, 2015, Pages 1-6

  Liu, Xiwei ^a   Min, Li ^a   Duan, Hong ^a   Shi, Rui ^a   Zhang, Wenli ^a   Hong, Song ^a   Tu, Chongqi ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cell cycle; Cell proliferation; IL1R2; Osteosarcoma; Short hairpin RNA (shRNA); U 2 OS

Indexed keywords

INTERLEUKIN 1 RECEPTOR TYPE II; LENTIVIRUS VECTOR; MESSENGER RNA; SHORT HAIRPIN RNA; IL1R2 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CANCER GENE THERAPY; CELL CYCLE ASSAY; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MTT ASSAY; OSTEOSARCOMA; U2OS CELL LINE; VIRAL GENE DELIVERY SYSTEM; BONE TUMOR; FLOW CYTOMETRY; GENE SILENCING; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HUMANS; OSTEOSARCOMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-1 TYPE II; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84919952176     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0364-2     Document Type: Article

References (36)

1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115:1531–43.
2. He JP, Hao Y, Wang XL, et al. Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev. 2014;15:5967–76.
3. Kansara M, Teng MW, Smyth MJ, et al. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14:722–35.
4. Mirabello L, Pfeiffer R, Murphy G, et al. Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control. 2011;22:899–908.
5. Longhi A, Pasini A, Cicognani A, et al. Height as a risk factor for osteosarcoma. J Pediatr Hematol Oncol. 2005;27:314–8.
6. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845–52.
7. Hegyi M, Semsei AF, Jakab Z, et al. Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. Pediatr Blood Cancer. 2011;57:415–22.
8. Aponte-Tinao L, Ayerza MA, Muscolo DL, et al. Survival, recurrence, and function after epiphyseal preservation and allograft reconstruction in osteosarcoma of the knee. Clin Orthop Relat Res. 2014. http://link.springer.com/article/10.1007%2Fs11999-014-4028-5.
9. Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long- term outcome—the French pediatric experience. Cancer. 2005;104:1100–9.
10. Meyers PA, Healey JH, Chou AJ, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer. 2011;117:1736–44.
11. Briccoli A, Rocca M, Salone M, et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer. 2005;104:1721–5.
12. Boraschi D, Tagliabue A. The interleukin-1 receptor family. Semin Immunol. 2013;25:394–407.
13. Peters VA, Joesting JJ, Freund GG. IL-1 receptor 2 (IL-1R2) and its role in immune regulation. Brain Behav Immun. 2013;32:1–8.
14. McMahan CJ, Slack JL, Mosley B, et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 1991;10:2821–32.
15. Ricote M, García-Tuñón I, Bethencourt FR, et al. Interleukin-1 (IL-1 alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer. 2004;100:1388–96.
16. Leshem O, Madar S, Kogan-Sakin I, et al. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One. 2011;6:e21650.
17. Jones DZ, Ragin C, Kidd NC, et al. The impact of genetic variants in inflammatory-related genes on prostate cancer risk among men of African Descent: a case control study. Hered Cancer Clin Pract. 2013;11:19.
18. Kondera-Anasz Z, Mielczarek-Palacz A, Switała J. Significantly increased interleukin-1A and interleukin-1 soluble type II receptor levels in women with ovarian cancer. Ginekol Pol. 2003;74:761–6.
19. Laios A, O’Toole SA, Flavin R, et al. An integrative model for recurrence in ovarian cancer. Mol Cancer. 2008;7:8.
20. Keita M, AinMelk Y, Pelmus M, et al. Endometrioid ovarian cancer and endometriotic cells exhibit the same alteration in the expression of interleukin-1 receptor II: to a link between endometriosis and endometrioid ovarian cancer. J Obstet Gynaecol Res. 2011;37:99–107.
21. Pantschenko AG, Pushkar I, Anderson KH, et al. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol. 2003;23:269–84.
22. Jung MY, Kim SH, Cho D, et al. Analysis of the expression profiles of cytokines and cytokine- related genes during the progression of breast cancer growth in mice. Oncol Rep. 2009;22:1141–7.
23. Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood. 2008;111:2339–46.
24. Fennell DA, Myrand SP, Nguyen TS, et al. Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study. PLoS One. 2014;9:e107455.
25. Sun H, Chua MS, Yang D, et al. Antibody arrays identify potential diagnostic markers of hepatocellular carcinoma. Biomark Insights. 2008;3:1–18.
26. Rückert F, Dawelbait G, Winter C, et al. Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis. PLoS One. 2010;5:e12243.
27. Stadnyk AW, Yeung MM, Yan SR. Human colon carcinomas constitutively express and shed type II IL-1 receptor, an IL-1 antagonist. Dig Dis Sci. 2003;48:1737–44.
28. Tömböl Z, Szabó PM, Molnár V, et al. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific targetprediction, and pathway analysis. Endocr Relat Cancer. 2009;16:895–906.
29. Szabó DR, Baghy K, Szabó PM, et al. Antitumoral effects of 9-cis retinoic acid in adrenocortical cancer. Cell Mol Life Sci. 2014;71:917–32.
30. Chen P, Xi Q, Wang Q, et al. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer. Med Oncol. 2014;31:235.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63.
33. Su PF, Hu YJ, Ho IC, et al. Distinct gene expression profiles in immortalized human urothelial cells exposed to inorganic arsenite and itsmethylated trivalent metabolites. Environ Health Perspect. 2006;114:394–403.
34. Chang SY, Su PF, Lee TC. Ectopic expression of interleukin-1 receptor type II enhances cell migration through activation of the pre-interleukin 1 alpha pathway. Cytokine. 2009;45:32–8.
35. Seo KW, Holt R, Jung YS, et al. Fluoroquinolone-mediated inhibition of cell growth, S-G2/M cell cycle arrest, and apoptosis in canine osteosarcoma cell lines. PLoS One. 2012;7:e42960.
36. Tsui KC, Chiang TH, Wang JS, et al. Flavonoids from Gynostemma pentaphyllum Exhibit Differential Induction of Cell Cycle Arrest in H460 and A549 Cancer Cells. Molecules. 2014;19:17663–81.